The prevalence of prediabetes is increasing in young adults and patients undergoing coronary angiography. However, whether prediabetes is a considerable risk factor for all-cause mortality remains undetermined in young patients undergoing coronary angiography.
Methods
In this study, we retrospectively included 8868 young patients (men aged < 45 years, women aged < 55 years) who underwent coronary angiography (CAG). Patients were categorized as normoglycemic, prediabetes and diabetes according to the HbA1c level or documented history of diabetes. The association of all-cause mortality with diabetes and prediabetes was detected by Cox proportional hazards regression analysis.
Results
A total of 3240 (36.5%) among 8868 young patients receiving CAG were prediabetes and 2218 (25.0%) were diabetes. 728 patients died during a median follow-up of 4.92 years. Compared to the normoglycemic group, prediabetes increased the risk of all-cause mortality in young CAG patients by 24%(adjusted HR: 1.24, 95% CI: 1.04–1.49, p = 0.019) and diabetes increased the risk of all-cause mortality by 46%(adjusted HR:1.46, 95% CI:1.2–1.79, p < 0.001). Subgroup analysis showed that diabetes and prediabetes increased the risk of death mainly in patients without comorbidities.
Conclusion
Prediabetes accounts for more than one-third of the young adults undergoing CAG and was associated with an increased risk of all-cause mortality, active prevention strategy should be considered for these patients.
Hinweise
Yibo He, Hongyu Lu, and Yihang Ling contributed equally to this work and share first authorship
The original online version of this article was revised: The error in the funding note has been corrected.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ACEI
Angiotensin-converting enzyme inhibitor
ARB
Angiotensin receptor blocker
ADA
American Diabetes Association
AMI
Acute myocardial infarction
CAG
Coronary artery angiography
CAD
Coronary artery disease
CKD
Chronic kidney disease
CHF
Congestive heart failure
ECMS
Electronic clinical management system
eGFR
Estimated glomerular filtration rate
HT
Hypertension
LDL-C
Low-density lipoprotein cholesterol
PCI
Percutaneous coronary intervention
STEMI
ST-elevation myocardial infarction
TC
Total cholesterol
TG
Triglycerides
Introduction
Prediabetes is defined as the intermediate metabolic state between normoglycemia and diabetes mellitus. According to the American Diabetes Association (ADA) guidelines, prediabetes is defined as the level of HbA1c ranged from 38.8 mmol/mol (5.7%) to 47.5 mmol/mol (6.4%) for patients without known diabetes [1]. Previous studies have demonstrated the current prevalence of prediabetes is elevated, especially in the young population [2, 3]. In a survey of the Chinese general population, the prevalence of prediabetes in adults aged 30–39 years has reached 29.9% [4]. On the other hand, prediabetes was reported more prevalent in patients undergoing coronary angiography (CAG) than in the general population [5, 6]. Marín also found that prediabetes is common in young patients with ST-elevation myocardial infarction (STEMI). As a conventional method for diagnosis of coronary artery disease (CAD), the number of people undergoing coronary artery angiography is increasing [7], with a notable increase in young adults [8]. However, there is still a lack of research on the prevalence and impact of prediabetes on young patients undergoing CAG in China.
Studies have shown that prediabetes increases the risk of cardiovascular disease (CVD) and kidney disease with increased mortality [9, 10], while reversing to normoglycemia from prediabetes prompted reducing the corresponding risk [11]. Compared with old adults, young adults with abnormal blood glucose are reported with a higher risk of mortality [12]. However, it has also been found that in patients with CAD, prediabetes is not associated with the risk of cardiovascular mortality and all-cause mortality [13]. The relationship between prediabetes and cardiovascular disease and all-cause mortality remains equivocal in young patients.
Anzeige
In this study, we aim to investigate the prevalence and effect of prediabetes on all-cause mortality in a large, multi-center cohort of young patients undergoing coronary angiography in China.
Methods
Study population
This cohort study analyzed data from the Cardiorenal Improvement II (CIN-II) study, which is a multi-center cohort study with patients enrolled at five large tertiary hospitals (Cardiorenal Improvement II, ClinicalTrials.gov NCT05050877) in China. A total of 145,267 patients undergoing CAG from January 2007 to December 2020 were enrolled. We included patients of young age (men < 45, women < 55; n = 15,358). Patients with missing data on glycosylated hemoglobin (HbA1c) level (n = 5,904), or follow-up information (n = 96), with scheduled cardiac surgery (n = 490) were excluded. Eventually, 8868 patients undergoing CAG were enrolled (Fig. 1). The study was approved by the ethics committee of the participant hospital and complied with the Declaration of Helsinki.
Fig. 1
Flowchart of the study
×
Data collection
Data was extracted from the electronic clinical management system (ECMS) of each participant hospital. The baseline data comprised the demographic details, medical history, laboratory examination and other clinical information. Patients were subjected to follow-up by trained nurses or assistants after discharge and the follow-up data was obtained by telephone or clinical visits to the patients, otherwise the National Death Registry Database was searched for mortality outcome if necessary.
Definition and outcome
The ADA’s standards in HbA1c were adopted for the definition of prediabetes and diabetes. Patients with HbA1c lower than 38.8 mmol/mol (5.7%) and no prior diagnosis of all kinds of diabetes were categorized as normoglycemic, with HbA1c ranging from 38.8 mmol/mol (5.7%) to 47.5 mmol/mol (6.4%) and no prior diagnosis of all kinds all diabetes were defined as prediabetes while HbA1c higher than 47.5 mmol/mol (6.5%) or with documented hypoglycemic therapy were defined as diabetes (Type II). The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [16], and chronic kidney disease (CKD) was defined as eGFR < 60 mL/min/1.73m2 [17]. Congestive heart failure (CHF) was defined as New York Heart Association class > 2 or Killip class > 1. Acute myocardial infarction (AMI), type 2 diabetes mellitus, and hypertension (HT) were defined according to the 10th Revision Codes of the International Classification of Diseases (ICD-10).
Anzeige
The primary outcome was the all-cause mortality which was acquired from the follow-up information recorded by trained staff, the research in the National Death Registry Database was also available for mortality outcome if necessary.
Statistical analysis
Continuous variables were presented as means (standard deviations [SD]) or median quartiles (IQRs), categorical variables were presented as frequency counts and percentages. Patients' demographic characteristics, medical histories, admission information, and clinical features were listed. One-way analysis of variance (ANOVA) was used to investigate differences between each group. Kaplan–Meier curves were constructed to visually represent time-to-event data, and log-rank tests were employed to evaluate survival across the groups. Covariates enrolled in the multivariate model were screened by stepwise cox regression analysis and based on the clinical significance, including age, gender, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), CKD, CHF, CAD, AMI, percutaneous coronary intervention (PCI), angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEI/ARB), beta-blocker, calcium channel blocker, uremic acid, estimated glomerular filtration rate, systolic blood pressure and history of smoking. Multiple imputation was performed for the missing data. To avoid the potential collinearity between variables, variance inflation factors (VIF) were calculated. Subgroup analyses were also performed according to different comorbidities including age, CAD, CHF, CKD, AMI, and PCI. P values derived from two-tailed tests, and values < 0.05 were deemed statistically significant. All statistical analyses were performed using R, version 4.0.3 software (R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics
A total of 8868 young patients (mean age 43.99 ± 6.90 years, 53.6% were men) undergoing CAG were enrolled in the study. 2218 (25.0%) patients were categorized as diabetes while 3240 (36.5%) were prediabetes. There were 4777 (54.4%) patients were diagnosed with CAD, 3608 (40.7%) patients underwent PCI, 3195 (36.4%) with hypertension, 1754 (20.0%) with acute myocardial infarction (AMI), 984 (11.2%) with CHF, and 511 (5.8%) with CKD. Compared to the normoglycemic group, patients with prediabetes and diabetes were older, more likely to be female and have comorbidities such as AMI, CHF, CKD, CAD, and hypertension. Their TG, TC and LDL-C were higher than those with normoglycemic, while the levels of high-density lipoprotein cholesterol (HDL-C) were lower. The details of the clinical baseline characteristics are shown in Table 1.
Table 1
Baseline characteristics according to the glycemic status
During a mean follow-up of 4.92 years, a total of 728 patients died including 209 in the normoglycemia group, 300 in the prediabetes group and 219 in the diabetes group. The time-to-event curves showed that patients with prediabetes had a increased risk in all-cause mortality compared with normoglycemic patients, and diabetes was associated with a higher risk of mortality (Fig. 2). Cox regression analysis showed that prediabetes and diabetes significantly increased all-cause mortality in young CAG patients by comparison to the normoglycemic group (adjusted HR: 1.24, 95% CI: 1.04–1.49, p = 0.019; adjusted HR:1.46, 95% CI:1.2–1.79, p < 0.001) (Fig. 3). The variance inflation factors showed no significant covariance among each of the incorporated covariates (VIF < 5).
Fig. 2
Kaplan–Meier curves of all-cause mortality
Fig. 3
Unadjusted and adjusted HRs and 95% CIs for the primary end point (all-cause mortality) of diabetes and prediabetes Model 1: unadjusted; Model 2: adjusted for age and gender; Model 3: adjusted for age, gender, triglycerides, low-density lipoprotein cholesterol, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, calcium channel blocker, uremic acid, estimated glomerular filtration rate, systolic blood pressure, history of smoking, and comorbidities including chronic kidney disease, congestive heart failure, coronary artery disease, acute myocardial infarction, percutaneous coronary intervention
×
×
Subgroup analysis
In the subgroup analysis, Cox regression analysis showed that diabetes increased the risk of mortality in patients without AMI, CAD, CHF, CKD, age ≥ 40 years old and those with or without receiving PCI at baseline (Fig. 4). On the other hand, prediabetes was associated with the elevated risk of mortality in patients without AMI, CAD, CHF, CKD, PCI and age < 40. However, the interactions between the subgroups regarding the effect of prediabetes and diabetes on mortality were insignificant generally.
Fig. 4
Forest plots of hazard ratio for all-cause mortality in subgroup
×
Discussion
In summary, our data showed that prediabetes increased the risk of all-cause mortality in young patients undergoing CAG by 24% and diabetes increased the risk of all-cause mortality by 45% compared to the normoglycemic group. It emphasizes the additional risk of prediabetes for young patients beyond diabetes, which should be considered earlier in prevention.
There are few studies demonstrating the prevalence and importance of prediabetes in young adults who underwent CAG. Among young STEMI patients, the prevalence of prediabetes was 24% [7]. In addition, the prevalence of prediabetes was significantly higher in young patients receiving CAG compared to the corresponding age group in the general population [3]. Our results indicated that over 1/3 of young patients were characterized as prediabetes, which emphasized the importance of routine testing for prediabetes in young patients undergoing CAG.
It was controversial whether prediabetes increases the risk of cardiovascular disease and all-cause mortality [14‐16]. Previous studies have demonstrated the increased risk of CVD and all-cause mortality were associated with the presence of prediabetes in young adults without diabetes and prior CVD [17]. In Japanese workers, the relationship between prediabetes and all-cause mortality has also been investigated [18]. However, an innovative cross-sectional study to reduce cardiovascular complications in diabetes (ARTEMIS) showed that prediabetes is not associated with the risk of cardiovascular mortality and all-cause mortality in patients with CAD [13]. In older adults, prediabetes and newly diagnosed diabetes are not significantly associated with a higher risk of all-cause mortality [19‐21]. Huang et al. found no significant association between prediabetes alone and long-term mortality in the general population, but the predictive power of prediabetes for the mortality risk appears to be stronger among low-risk populations (younger and White participants) [22].
Anzeige
Prediabetes was also defined according to various criteria in different guidelines and studies, including impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). IGT is defined as an oral glucose tolerance test 2-h plasma glucose of 7.8–11.0 mmol/L, while IFG is defined by the World Health Organization (WHO) and the ADA as fasting blood glucose of 6.1–6.9 mmol/L (IFG-WHO) and 5.6–6.9 mmol/L (IFG-ADA), respectively [23, 24]. According to Echouffo-Tcheugui’s study, prediabetes in different definitions was related to adverse prognostic risks, including cardiovascular disease, renal disease, and all-cause mortality, with varying effect sizes, depending on the definitions used [23]. Warren’s study reported that HbA1c was more specific than postprandial glucose in screening for prediabetes, improving risk discrimination for clinical complications [25]. On the other hand. a large cross-sectional study has shown that prediabetes is associated with worse outcomes, regardless of the definition adopted [26]. Huang et al. have revealed through meta-analysis that prediabetes was associated with an increased risk of adverse events regardless of different definitions both in the general population and patients with atherosclerotic cardiovascular disease [9, 27]. Nonetheless, further studies are warranted to verify whether the definition of prediabetes would affect the prognosis in the large-scale cohort study of young patients.
Our study showed that prediabetes and diabetes detected by HbA1c can predict a higher risk of all-cause mortality in young adults undergoing CAG. However, in the subgroup analysis, prediabetes and diabetes increased the risk of long-term mortality mainly in young patients received CAG without comorbidities at baseline and the association was insignificant in those patients with AMI, CAD, CHF, CKD or undergoing PCI at baseline. This may partially explain the controversy over prediabetes as a risk factor for all-cause mortality. In patients with existing comorbidities or older age, who have higher mortality and complex risk factors, the role of type 2 diabetes and prediabetes may be masked. However, in younger adults with fewer risk factors, prediabetes and type 2 diabetes may turn out to be one of the primary risk factors. In this study, we confirmed that in young patients undergoing CAG, prediabetes still appeared to be significantly associated with all-cause mortality. Therefore, prediabetes may remain a concern for young patients undergoing CAG.
Limitation
Several limitations exist in the study. First, as an observational study, our results were influenced by its nature and do not reflect direct cause-and-effect relationships. However, we included more patients compared with previous studies [28‐30] and our results still provided a reference for the debates on the prognostic impact of prediabetes. Second, although we have made adjustments for variables as much as we can, there could be potential confounding factors that we may have overlooked. We were unable to evaluate data from additional aspects since our data did not contain concrete causes of mortality and other adverse events. Third, we failed to investigate the evolution in glucose metabolism over time and we did not have sufficient data on fasting glycemia to evaluate the effect of prediabetes on mortality in various definitions. The possibility that the increase in mortality resulted from the conversion of prediabetes to diabetes cannot be excluded. Further study on tracking the changes of prediabetes in young patients receiving CAG is recommended.
Conclusion
In summary, our study demonstrated that prediabetes was common among young patients undergoing CAG and prediabetes was an independent risk factor for all-cause mortality among them, especially in patients without previous complications.
Anzeige
Acknowledgements
We appreciate the contribution of all study participants. The authors thank the follow-up staff of the Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, for their excellent work.
Declarations
Ethics approval and consent to participate
The Ethics Committee of the Guangdong Provincial People's Hospital approved the study (No. GDREC2019-555H-2). All participating sites received institutional review board approval from their own ethics committees. It was conducted in accordance with the principles of the Declaration of Helsinki.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Anzeige
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.
Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.
Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.
Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
